Companies: 10,795·Total market cap: $144.5T
Akero Therapeutics, Inc.

Akero Therapeutics, Inc.

AKRONASDAQHealthcare
$54.65
+$0.00(+0.00%)
Market Cap$4.5B
P/E Ratio—
52W High$58.4
52W Low$21.34
Overview
Stock ranking:Biotechnology·Healthcare·View All Market Cap Rankings →

Akero Therapeutics, Inc. (AKRO) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · AKRO · as of Jun 8, 2026

Key Statistics

EPS (TTM)$-3.74akro eps ttm · akro earnings per shareEarnings history
PE Ratio (TTM)—akro pe ratio ttm · akro price to earningsPE Ratio deep dive
Revenue (TTM)0.00akro revenue ttm · akro annual revenueFull revenue history
Dividend YieldNo Dividenddoes akro pay dividends · akro dividend yieldDividend history
Shares Outstanding67.1Makro shares outstanding · akro floatShares outstanding history
Next EarningsTBAakro earnings date · akro next earningsEarnings history

Explore Akero Therapeutics, Inc. Data

akro stock data · financials
Market Cap$4.5Bakro market cap · akro valuation
Analyst Forecast$48 · Buy
DividendsNo Dividenddoes akero therapeutics, inc. pay dividends · akro dividend yield
Revenue—akero therapeutics, inc. annual revenue · akro revenue
EarningsEPS $-3.75-29.76%akro earnings · akro eps
PE Ratio—akro pe ratio · akro price to earnings

Financial Snapshot

Full Financials
FY 2024Revenue$0.00
202220232024
akero therapeutics, inc. revenue · akro revenue 2024
FY 2024Net Income-$252.1M▼ 66.09% YoY
202220232024
akero therapeutics, inc. net income · akro profit 2024
FY 2024EPS$-3.75▼ 29.76% YoY
202220232024
akro eps · akero therapeutics, inc. earnings per share 2024
TTM:Revenue: $0.00Net Income: -$292.8MEPS: $-3.74View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy14 analystsis akro a buy · akro analyst rating
Strong Buy
0
Buy
10
Hold
4
Sell
0
Strong Sell
0
12-Month Price Target
$38.00Low
$54.65Current
$48.40Avg Target11.44% downside
$56.00High
akro price target · akro 12 month forecast

Total: 14 · Buy rate: 71.4%

The AKRO analyst consensus is Buy, based on ratings from 14 Wall Street analysts over the past 3 months. The average 12-month price target is $48.40, representing -11.44% downside from the current price of $54.65.

Stock Performance

Full History
1D+0.00%
1W+0.00%
1M+0.00%
3M+17.55%
YTD+0.00%
1Y+108.91%
5Y+89.17%

About Akero Therapeutics, Inc.

CEOAndrew Cheng
IPO DateJun 20, 2019
Employees69
CountryUS
Websiteakerotx.com

Akero Therapeutics, Inc. a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The …

BiotechnologyHealthcareNASDAQUS

what is akero therapeutics, inc. · akro stock overview · akero therapeutics, inc. company profile · who is akero therapeutics, inc. ceo · akro NASDAQ · akero therapeutics, inc. headquarters · akero therapeutics, inc. business segments

About Stock Overview & Key Data

Akero Therapeutics, Inc. (AKRO) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jun 20, 2019. As of the latest trading session, AKRO stock price is $54.65, with a market capitalization of $4.5B. The stock has returned +108.91% over the past 12 months and +0.00% year-to-date.

According to 14 Wall Street analysts, the consensus rating for Akero Therapeutics, Inc. stock is Buy, with an average 12-month price target of $48.40. In fiscal year 2024, Akero Therapeutics, Inc. reported revenue of — and net income of -$252.1M. For detailed data — including Akero Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Akero Therapeutics, Inc. (AKRO) stock price is $54.65. The stock is traded on NASDAQ under the ticker symbol AKRO. The 52-week range is $21.34 – $58.40.

AKRO stock priceAKRO quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice